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Abstract 
Background:  Nitrobenzoxadiazole derivatives (NBDs), including NBDHEX and the recently developed MC3181, are 
promising anticancer agents able to target glutathione transferase and inhibit both its catalytic activity and ability 
to sequester TNF-receptor associated factor 2 (TRAF2) and c-Jun N-terminal kinase (JNK). NBDs have been shown 
to impair the growth and survival of a broad-spectrum of tumor types, in vitro and in vivo. Herein, we evaluated the 
effects of the new compound MC3181 on U-2OS osteosarcoma cells and investigated the impact of both NBDHEX 
and MC3181 on autophagy.
Methods: Cell viability was evaluated by sulforhodamine B assay. The dissociation of the TRAF2-GSTP1-1 complex 
was detected by proximity ligation assay, while the phospho-activation of JNK was assessed by western blotting. The 
effects of NBDs on autophagy were evaluated by GFP-LC3 puncta formation, western blotting for LC3-II and p62, and 
LC3 turnover assay in the presence of bafilomycin A1. The role of JNK in the reduction of autophagic flux caused by 
NBDs was investigated using JNK1 shRNA-transfected cells. Fluorogenic caspase activity assay and flow cytometric 
analysis of DNA content were used to determine the cytotoxic effects of NBDs on JNK1-silenced cells.
Results: Similar to NBDHEX, MC3181 reduced viability and activated TRAF2/JNK signaling in U-2OS cells. Moreover, 
NBDs induced the accumulation of autophagic vesicles and LC3-II while reducing both basal and nutritional stress-
induced autophagic flux. Furthermore, increased levels of both LC3-II and the autophagy selective substrate p62 were 
observed in different tumor cell lines treated with NBDs, the concurrent increase of these markers being consistent 
with an impairment of autophagosome clearance. Autophagy inhibition by NBDs required JNK activity: NBDs caused 
autophagy inhibition and caspase-3 activation in JNK-positive U-2OS, but no autophagic flux inhibition or caspase-3 
activation in JNK-silenced cells.
Conclusions: Our demonstration that NBDs can act as late-phase autophagy inhibitors opens new opportunities to 
fully exploit their therapeutic potential. This may not rely solely on their effectiveness in inducing cell cycle arrest and 
apoptosis, but also on their ability to weaken the capacity of tumor cells to endure stress conditions via autophagy. In 
addition, this study provides evidence that JNK can participate in impairing autophagy.
Keywords: Nitrobenzoxadiazoles, Glutathione transferase, c-Jun N-terminal kinase, Autophagy, Osteosarcoma
© 2016 Palumbo et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/




*Correspondence:  camilla.palumbo@uniroma2.it; caccuri@uniroma2.it 
1 Department of Clinical Sciences and Translational Medicine, University 
of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
2 Department of Experimental Medicine and Surgery, University of Rome 
Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
Full list of author information is available at the end of the article
Page 2 of 12Palumbo et al. J Transl Med  (2016) 14:37 
Background
NBDHEX (6-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)thio) 
hexan-1-ol) is the leading compound of a class of 
nitrobenzoxadiazole derivatives (NBDs) with promising 
anticancer properties. Indeed, by targeting glutathione 
transferases (GSTs) these compounds have been shown 
to impair growth and survival of cancer cells at multiple 
levels [1–5]. First, NBDs act as strong inhibitors of GSTs 
catalytic activity; accordingly, they can hinder the GST-
mediated conjugation of several electrophilic anticancer 
drugs to reduced glutathione (GSH), which in turn would 
result in drug detoxification and extrusion from the cell 
via specific export pumps [1, 6–9]. Moreover, NBDHEX 
is not a substrate of P-glycoprotein (P-gp) and multidrug 
resistance-associated protein 1 (MRP1) transporters, so 
that it accumulates in tumor cells, overcoming another 
major mechanism of cancer cell chemoresistance [10–
12]. Secondly, NBDs are able to disrupt the interaction 
between the GST isoform GSTP1-1 and key signaling 
effectors involved in the regulation of cell survival and 
proliferation, namely the adaptor protein TNF-Receptor 
associated factor 2 (TRAF2) and the c-Jun N-terminal 
kinase (JNK) [2, 3, 13, 14]. The NBDs-induced release 
of TRAF2 from the complex with GSTP1-1 leads to 
the activation of the apoptosis signal-regulating kinase 
(ASK1), which in turn activates both p38 and JNK mito-
gen-activated protein kinase (MAPK) signaling pathways 
[3, 8]. As a result, p38 causes cell cycle arrest, while JNK 
promotes apoptosis, the activation of this MAPK pro-
apoptotic pathway being further sustained by the NBDs-
induced release of JNK from the complex with GSTP1-1 
[3, 9]. Therefore, NBDs can exert antitumor effects either 
per se or by potentiating the efficacy of conventional 
anticancer drugs whose action relies on the activation of 
these MAPK pathways [9].
In fact, NBDHEX has shown a broad-spectrum of 
activity against cancer cells of different origins, includ-
ing osteosarcoma, Ewing’s sarcoma, melanoma, meso-
thelioma, lung and hepatic carcinoma and different types 
of leukemia, either alone or in combination with anti-
tumor drugs such as cisplatin, doxorubicin, vincristine, 
and temozolomide [2, 3, 10, 15–18]. Moreover, in in vivo 
studies performed on various tumor types xenografted in 
mice, NBDHEX proved to be effective in reducing both 
cancer growth and metastatic spread and was well toler-
ated [17, 19, 20].
Besides NBDHEX, the most promising compound 
among the NBDs is the recently developed water-solu-
ble analogue MC3181 (2-(2-(2-((7-nitrobenzo[c][1,2,5]
oxadiazol-4-yl)thio)ethoxy)ethoxy)ethanol) [5, 21]. This 
compound bears two oxygen atoms within the alkyl chain 
bound at the C4 position of the NBD scaffold, resulting in 
a more than 50-fold increase in aqueous solubility com-
pared to NBDHEX [5].
Given the encouraging results obtained with NBDHEX 
on osteosarcoma models [3, 15, 20], we performed 
experiments initially aimed at evaluating the activity of 
the new compound MC3181 on U-2OS human osteo-
sarcoma cells cultured in  vitro. Treatment with either 
MC3181 or the parent compound NBDHEX caused the 
accumulation of cytoplasmic vacuoles in U-2OS cells and 
prompted us to investigate the possible effects of these 
NBDs on autophagy. We here demonstrate that NBDs 




U-2OS human osteosarcoma cells were purchased from 
the American Type Culture Collection (ATCC) and 
grown in IMDM supplemented with 10  % FBS, 2  mM 
l-glutamine, 100 U/ml penicillin and 100  µg/ml strep-
tomycin (EuroClone, Milan, Italy). Experiments were 
also performed with MM-B1 biphasic malignant meso-
thelioma cells [18] and with the HT-29 and COLO 205 
colorectal adenocarcinoma and MCF-7 breast adeno-
carcinoma cells of the NCI-60 cell line panel. MCF-7, 
COLO 205 and HT-29 cells were grown in RPMI 1640, 
and MM-B1 in DMEM (EuroClone), both media being 
supplemented as above. NBDHEX and MC3181 were 
synthesized as previously reported [1, 5]. For cell treat-
ments NBDs were dissolved in DMSO and diluted in 
cell medium, with the final DMSO concentration never 
exceeding 0.01  % (v/v); control cultures received an 
equivalent amount of DMSO vehicle. The late-stage 
autophagy inhibitor chloroquine diphosphate (CQ) was 
purchased from Sigma-Aldrich (Milan, Italy).
Cell viability studies
Cells (7–35  ×  103, depending on the cell line) were 
seeded in triplicate in 96-well plates and cultured for 
24  h, after which they were exposed to increasing con-
centrations (0.1–50 μM) of MC3181 and NBDHEX. Cell 
viability was quantified after 48 h of treatment by the sul-
forhodamine B (SRB) assay [22]. The concentrations of 
drug required for 50  % inhibition of cell viability (IC50) 
were determined from dose–response curves.
Proximity ligation assay (PLA)
PLA and confocal laser scanning microscopy analysis of 
TRAF2-GSTP1-1 complexes were performed as previ-
ously described [14]. Briefly, formaldehyde-fixed and 
methanol-permeabilized U-2OS cells were incubated 
with a mouse anti-GSTP1-1 and a rabbit anti-TRAF2 
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antibody (Cell Signaling Technology, Beverly, MA, 
USA) followed by Duolink PLA Rabbit MINUS and PLA 
Mouse PLUS proximity probes (Olink Biosciences, Upp-
sala, Sweden). Proximity ligation was performed using 
the Duolink Far-Red in situ detection reagent kit (Olink 
Bioscences), according to the manufacturer’s protocol. At 
the end of the procedure each TRAF2-GSTP1-1 complex 
generated a fluorescent red spot. DAPI was used to coun-
terstain cell nuclei. Fluorescence was detected using a 
Fluoview 1000 Olympus system equipped with an Olym-
pus IX-81 inverted microscope, as previously detailed 
[14]. The BlobFinder software (Olink Bioscience) was 
used for PLA image analysis. Fluorescent signals from 
rolling circle amplification products were defined and 
counted per cell.
Western blotting
Western blot analysis was performed using the following 
primary antibodies: anti-phospho-JNK (Thr183/Tyr185) 
and anti-JNK1 (Cell Signaling Technology); anti-LC3 
(Novus Biologicals, Littleton, CO, USA) [23]; anti-p62/
SQSTM1 (Santa Cruz Biotechnology, Santa Cruz, CA, 
USA) [24]; anti-β-actin (Sigma-Aldrich). The immune 
complexes were visualized using an enhanced chemi-
luminescence detection system (Pierce, Rockford, IL, 
USA). Densitometric analysis of autoradiographic bands 
was performed using the NIH Image J software (National 
Institutes of Health, Bethesda, MD, USA).
GFP‑LC3 transfection
U-2OS cells were transfected with the pEGFP-LC3 
plasmid [25], kindly provided by Professor Yoshimori 
(Department of Genetics, Osaka University, Osaka, 
Japan), using the calcium phosphate/BES method [26]. 
After about 2  weeks of selection in G418-containing 
medium (400 μg/ml; Sigma-Aldrich) and one additional 
week of growth in medium without G418, the entire pop-
ulation of transfected cells was used for GFP-LC3 puncta 
formation assays [25, 27]. The formation of puncta was 
evaluated under an Olympus BX50 fluorescence micro-
scope equipped with a digital camera.
Assessment of autophagic flux by LC3 turnover assay
U-2OS cells were seeded in duplicate at a density of 
2 × 104 cells/cm2, cultured for 24 h, treated with NBDs 
in medium containing 10 or 0.2 % FBS for an additional 
24 h, and then lysed in triple-detergent lysis buffer. Three 
hours before lysis, one of the duplicate cultures was incu-
bated with 100 nmol/l of the late-stage autophagy inhibi-
tor bafilomycin A1 (BAF; Sigma-Aldrich), while the other 
was incubated with the BAF vehicle DMSO. Cell lysates 
were analyzed by western blotting with anti-LC3 and 
anti-β-actin antibodies. After densitometric analysis of 
autoradiographic bands, the autophagic flux indexes of 
NBDs-treated and untreated cultures were calculated 
as the difference in LC3-II/actin ratios between samples 
plus and minus BAF [28–30]. The autophagic flux index 
of NBD-treated cultures was expressed in proportion to 
that of untreated cultures, which was arbitrarily set equal 
to 1.
JNK1 RNA interference
Vectors for JNK1 RNA interference were purchased 
from OriGene Technologies, Rockville, MD, USA. 
U-2OS cells were calcium phosphate/BES-transfected 
[26] with pGFP-V-RS vectors carrying either a 29-mer 
short hairpin RNA (shRNA) for human JNK1 (MAPK8; 
vector TG320484) or a 29-mer scrambled shRNA cas-
sette (vector TR30013). Transfected cells were selected 
with puromycin (1 μg/ml; Sigma-Aldrich) and individual 
clones were expanded and characterized for JNK1 pro-
tein expression levels. One JNK1 shRNA clone and one 
scrambled shRNA clone were chosen for functional stud-
ies, which were performed using cells grown for about 
1 week in the absence of puromycin.
Caspase activity assay
Caspase activity was measured as previously described 
[2]. Briefly, lysates from 1 × 106 U-2OS cells were assayed 
using the fluorogenic caspase-3 substrate N-acetyl-Asp-
Glu-Val-Asp-7-amido-4-trifluoromethylcoumarin (Ac-
DEVD-AFC, Sigma-Aldrich). Ac-DEVD-AFC cleavage 
was measured with a fluorometer equipped with a 400-
nm excitation filter and a 505-nm emission filter. The rate 
of fluorescence increase (ΔF/min) was calculated and 
results were expressed as ΔF/min × 106 cells.
Analysis of cellular DNA content by flow cytometry
U-2OS cells were fixed with 70  % ethanol, stained with 
50 mg/ml propidium iodide in a buffer containing 10 mg/
ml RNase and 1  % Triton X-100, and analyzed with a 
FACSCalibur flow cytometer (BD Bioscences, San Jose, 
CA, USA). Data analysis was performed using the FlowJo 
8.8.6 software (Tree Star, Ashland, OR, USA).
Statistical analysis
The experiments were repeated at least three times. Sta-
tistical analysis was performed by Student’s two-tailed t 
tests, with a significance threshold set at p < 0.05.
Results
Similar to the parent compound NBDHEX, MC3181 
reduces viability and activates TRAF2/JNK signaling 
in osteosarcoma cells
We first evaluated the effects of MC3181 on viability of 
U-2OS human osteosarcoma cells. Similar to NBDHEX, 
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MC3181 reduced the viability of U-2OS cells at concen-
trations in the low micromolar range, the calculated IC50 
values after a 48-h treatment being 0.9 μM for NBDHEX 
and 1.1  μM for MC3181 (Table  1). Our group has pre-
viously demonstrated that NBDs trigger the activation 
of JNK signaling in tumor cell lines of various origins 
[2, 5, 11, 18]. In particular, we already documented that 
NBDHEX dissociates the complex between GSTP1-1 
and TRAF2, and induces the activation of JNK in U-2OS 
cells [3, 14]. By monitoring the TRAF2-GSTP1-1 interac-
tion in situ by PLA (Fig. 1a) and the phospho-activation 
of JNK by western blotting (Fig.  1b) over a 6-h time-
course, we here show that MC3181 shares the property 
of the parent compound to promote TRAF2/JNK sign-
aling activation in U-2OS cells. Of note, the decrease in 
the amount of TRAF2-GSTP1-1 complex observed in 
MC3181-treated cells was not related to variations in the 
levels of the individual proteins (not shown). 
MC3181 and NBDHEX induce accumulation 
of autophagosomes
U-2OS cultures treated with either MC3181 or NBDHEX 
were characterized by the presence of both dead cells 
and cells showing a notable degree of cytoplasmic vacu-
olization, suggestive of the accumulation of autophagic 
vesicles (Fig. 2a). The hypothesis that NBDs could induce 
an accumulation of autophagosomes was confirmed by 
puncta formation assays performed using U-2OS cells 
transfected with a GFP-LC3 expression vector (Fig. 2b). 
Transfected cells left untreated displayed variable 
Table 1 NBDHEX and  MC3181 IC50 values for  U-2OS 
and tumor cell lines of different histotypes
IC50 values (mean ± SEM, n ≥ 3) after 48 h of treatment with NBDs, as 
determined from cell viability dose–response curves
Cell line NBDHEX (μM) MC3181 (μM)
U-2OS 0.9 ± 0.1 1.1 ± 0.1
MM-B1 1.3 ± 0.1 1.6 ± 0.2
MCF-7 1.6 ± 0.1 1.5 ± 0.1
COLO 205 5.3 ± 0.4 6.5 ± 0.2
HT-29 11.0 ± 0.4 15.8 ± 0.8
Fig. 1 Effects of MC3181 on TRAF2/JNK signaling in U-2OS cells. a Confocal microscopy for the in situ detection of the TRAF2-GSTP1-1 complex in 
cells treated with vehicle (CTRL) or 5 μM MC3181 (i.e. a concentration about five times the IC50 value) for the indicated times. The TRAF2-GSTP1-1 
complex was visualized by PLA, which generates fluorescent dots (red) when the two proteins are in close proximity. DAPI (blue) was used to 
counterstain cell nuclei. Scale bar 10 μM. b Amount per cell of TRAF2-GSTP1-1 complex as calculated from the analysis of PLA images (mean ± SEM, 
n ≥ 3); *p < 0.05. c Western blot analysis of JNK phospho-activation in cells treated with vehicle (CTRL) or 5 μM MC3181 for the indicated times. The 
filter was probed with anti-phospho-JNK (p-JNK) and anti-JNK1 antibodies; β-actin was used to ensure equal loading and transfer of samples
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levels of GFP-LC3 fluorescence, diffuse in appearance 
and mainly localized to the nuclei; conversely, in trans-
fected cells treated with either MC3181 or NBDHEX, 
GFP-LC3 was partly redistributed into numerous cyto-
plasmic puncta representing bona fide autophagosomes 
[27, 31]. Moreover, GFP-LC3 translocation from the 
nucleus to cytoplasmic dots appeared nearly complete in 
cells treated with the late-stage autophagy inhibitor CQ 
(Fig. 2b), used as positive control for autophagic vesicles 
accumulation [29].
MC3181 and NBDHEX induce accumulation of both LC3‑II 
and the selective autophagy substrate p62
The number of autophagosomes is known to correlate 
with the amount of LC3-II protein, which is formed by 
lipidation of the cytosolic LC3-I protein [28]. In line 
with the above reported findings, wild type U-2OS cells 
treated with NBDs for 48 h had increased amounts of the 
autophagosome-associated LC3-II protein as assessed by 
western blot analysis (Fig.  2c) [28]. Moreover, following 
NBDs treatment variably increased levels of LC3-II were 
also observed in a panel of tumor cell lines (including 
Fig. 2 MC3181 and NBDHEX induce accumulation of both autophagic vesicles and the selective autophagy substrate p62. a Morphology of U-2OS 
cells treated with vehicle (CTRL), 5 μM MC3181 or 5 µM NBDHEX for 48 h, viewed under an Olympus IX50 inverted microscope equipped with a 
digital camera. Original magnification ×200. b Puncta formation assay on U-2OS GFP-LC3 cells treated with vehicle (CTRL), 5 μM NBDs or 10 μM 
CQ for 48 h. Cells were photographed using a fluorescence microscope equipped with a digital camera. Original magnification ×400. c Immuno-
blot analysis for LC3-II and p62 in lysates from U-2OS, MM-B1, MCF-7, COLO 205 and HT-29 cells treated with vehicle (CTRL), 5 μM MC3181 or 5 µM 
NBDHEX for 48 h. β-Actin was used to ensure equal loading and transfer of samples. LC3-II/β-actin and p62/β-actin densitometric ratios are also 
reported: those of MC3181- and NBDHEX-treated samples were expressed in proportion to those of CTRL samples, which were arbitrarily set, equal 
to 1
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malignant mesothelioma, breast and colon carcinoma) 
characterized by different degrees of sensitivity to the 
cytostatic/cytotoxic effects of these compounds (Fig. 2c; 
Table 1).
The accumulation of autophagic vesicles and LC3-II 
induced by NBDs could be due to an increased genera-
tion of autophagosomes, to a decreased autophagosomal 
maturation/degradation or to a combination of both pro-
cesses [27, 28]. In order to understand whether the net 
effect of NBDs would be an enhanced or reduced clear-
ance of autophagy substrates, we performed western blot 
analysis for p62 (SQSTM1), one of the specific substrates 
that are selectively degraded through the autophagy-
lysosomal pathway [28]. In U-2OS cells p62 levels were 
very low to undetectable, in line with previous reports 
[32, 33]. On the other hand, in MM-B1, MCF-7, COLO 
205 and HT-29 cells p62 was detectable in basal condi-
tions and found to increase upon treatment with either 
NBD compound (Fig. 2c). The concurrent increase of p62 
and LC3-II in these cell types indicates that NBDs cause 
an accumulation of autophagic vesicles at least in part 
via an impairment of autophagosome maturation/degra-
dation, in this respect behaving as late-stage autophagy 
inhibitors [27, 28]. Based on the increase of both LC3-II 
and p62 levels, NBDHEX demonstrated a higher efficacy 
in reducing autophagosome clearance as compared to 
MC3181 (Fig. 2c).
NBDs impair both basal and nutritional stress‑induced 
autophagic flux
The term “autophagic flux” refers to the dynamic 
equilibrium between autophagosome formation and 
clearance by lysosomes. In other words, autophagic 
flux is the rate at which material is actually cleared 
from the cell by autophagy. Based on the observa-
tion that LC3-II is degraded in autophagolysosomes, 
autophagic flux can be quantified by measuring LC3 
turnover [27, 28]. Accordingly, definite proof of 
the autophagy-inhibitory effect of NBDs in U-2OS 
cells was obtained by LC3 turnover assay as follows: 
we performed western blot analysis for LC3-II on 
lysates from U-2OS cells untreated and NBDs-treated 
for 24  h, incubated or not with the inhibitor of 
autophagosomal degradation BAF for 3 h before lysis, 
as recommended [34] (Fig.  3a). The autophagic flux 
indexes of the cultures were then calculated as the 
difference in the amount of LC3-II in the presence 
and absence of BAF (Fig.  3b), such difference repre-
senting the amount of LC3-positive autophagosomes 
degraded through the lysosome during the last 3  h 
of culture [28–30]. Of note, in these experiments we 
chose an endpoint of 24  h, instead of 48  h as in the 
experiments of Figs.  1 and 2, this in order to assess 
autophagic flux before the NBDs could induce signifi-
cant cell death [14]. U-2OS cells treated with NBDs 
for 24 h had increased levels of LC3-II as compared to 
the untreated controls (Fig. 3a, black bars of Fig. 3b). 
Following the addition of BAF the amount of LC3-II 
was more than doubled in NBD-untreated cultures, 
whereas it was increased to a much lower degree in 
NBDs-treated cultures (Fig.  3a, gray bars vs. black 
bars in Fig. 3b). These results indicate that, albeit with 
different efficacy, MC3181 and NBDHEX cause an 
impairment of autophagic flux in U-2OS cells. Indeed, 
treatment with 5  μM MC3181 or NBDHEX reduced 
the autophagic flux index of U-2OS cultures from 1 
to about 0.4 and 0.2, respectively (Fig. 3c). Figure 3d–f 
shows the dose-dependent trend in the reduction of 
the autophagic flux obtained by treating U-2OS cells 
with NBDHEX in the 0.5–5 μM concentration range.
We next investigated whether, in addition to basal 
autophagy, the NBDs could impair the increased 
autophagic flux typical of cells grown under stress con-
ditions, such as for instance under a reduced availabil-
ity of nutrients. Representative experiments illustrated 
in Fig.  3g–i demonstrate that the autophagic flux index 
of cells grown for 24 h in the presence of 0.2 % FBS was 
about twice that of cells grown in 10 % FBS. Such nutri-
tional stress-induced increase of the autophagic flux was 
reduced by treatment with MC3181 and completely abol-
ished by NBDHEX.
Overall, these data provide evidence that MC3181 and, 
to a higher extent, NBDHEX can impair both basal and 
nutritional stress-induced autophagic flux.
JNK silencing relieves the impairment of autophagic flux 
induced by NBDs
Previous findings by our group and the results reported 
hitherto demonstrate that treatment with NBDs triggers 
the activation of JNK, along with other signaling path-
ways, and leads to autophagic flux impairment and apop-
tosis in U-2OS cells [3, 14]. In many studies, however, 
the activation of JNK by different types of stress signals 
is reported to induce autophagy [35, 36], with only two 
recent papers describing JNK as a negative autophagy 
regulator [37, 38]. Thus, in order to shed light on JNK’s 
role in the reduction of autophagic flux caused by NBDs, 
we generated a U-2OS subline with deficient JNK1 
expression by stable transfection of the parental cells with 
an shRNA expression vector. As shown in Fig. 4a, JNK1 
was almost undetectable by western blot analysis in the 
JNK1 shRNA-transfected subclone, whereas in untrans-
fected and scrambled shRNA-transfected U-2OS it was 
expressed at similar levels. Furthermore, western blot 
analysis with an anti-pan-phospho-JNK antibody, rec-
ognizing both the ubiquitous JNK1 and JNK2 isoforms 
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[36], showed the absence of phospho-active forms of 
JNK in JNK1-silenced cells treated with NBDHEX while 
a sustained phospho-activation of JNK was induced by 
NBDHEX in scramble-transfected cells (Fig.  4b). These 
findings exclude the possibility that NBDs treatment may 
lead to the activation of JNK2 in JNK1-silenced U-2OS 
Fig. 3 Effect of NBDs on the autophagic flux of U-2OS cells. a LC3 turnover assays in basal conditions. Lysates from cells treated with vehicle (CTRL), 
5 μM MC3181 or 5 μM NBDHEX for 24 h, incubated or not with 100 nmol/l BAF for 3 h before lysis, were subjected to western blot for LC3-II and 
β-actin. b LC3-II/β-actin ratios determined from the densitometric analysis of the autoradiograms shown in a expressed in arbitrary units (a.u.). 
c Autophagic flux indexes calculated from the data illustrated in b as the difference in LC3-II/actin ratios between samples plus and minus BAF, 
expressed in arbitrary units (a.u.). d Dose–response effect of NBDHEX on basal autophagic flux. Lysates from cells treated with vehicle (CTRL) or 
0.5–5 μM NBDHEX for 24 h, incubated or not with 100 nmol/l BAF for 3 h before lysis, were subjected to western blot for LC3-II and β-actin. e LC3-
II/β-actin ratios determined from the densitometric analysis of the autoradiograms shown in d. f Autophagic flux indexes calculated from the data 
illustrated in e as the difference in LC3-II/actin ratios between samples plus and minus BAF. g LC3 turnover assays in nutritional stress conditions. 
Lysates from cells treated with vehicle (CTRL) or 5 μM NBDs in the presence of 0.2 % FBS for 24 h, incubated or not with 100 nmol/l BAF for 3 h 
before lysis, were subjected to western blot for LC3-II and β-actin. Lysates from cells grown for 24 h in the presence of 10 % FBS, incubated or not 
with BAF as above, were included to assess basal flux levels. h LC3-II/β-actin ratios determined from the densitometric analysis of the autoradio-
grams shown in g. i Autophagic flux indexes calculated from the data illustrated in h as the difference in LC3-II/actin ratios between samples plus 
and minus BAF
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cells, and demonstrate the functional knockdown of JNK 
signaling in the silenced clone.
Next, scramble-transfected and JNK1-silenced cells 
were tested in autophagic flux studies. In particular we 
performed LC3 turnover assays on cultures treated with 
NBDHEX, i.e. the compound that showed higher effi-
cacy in reducing the autophagic flux of wild type U-2OS. 
The effects of NBDHEX on scrambled shRNA cultures 
were similar to those observed in the parental U-2OS: 
as compared to the untreated cells, those treated with 
NBDHEX had an increased level of LC3-II (Fig. 4c, black 
bars of Fig.  4d) which was only slightly augmented fol-
lowing the addition of BAF (Fig.  4c, gray bars vs. black 
bars in Fig. 4d). In fact, NBDHEX reduced the autophagic 
flux index of scramble-transfected cells from 1 to 0.28 
(Fig.  4e). On the other hand, in JNK1-silenced cells 
NBDHEX caused an increase of LC3-II which, following 
the addition of BAF, was again significantly augmented 
(Fig. 4c, d). The magnitude of such increase was similar 
to that obtained after the addition of BAF to NBDHEX-
untreated JNK1-silenced cells (Fig.  4c, d). Indeed, 
NBDHEX caused no net modification of the autophagic 
flux in the JNK1-deficient subclone (Fig. 4e).
JNK silencing abolishes caspase‑3 activation and apoptosis 
induced by NBDs
Finally, JNK1-silenced cells were characterized in terms 
of sensitivity to the cytotoxic effects of NBDs. By using 
specific kinase inhibitors, we previously reported that in 
U-2OS cells NBDHEX causes a p38-dependent arrest in 
the G2/M phase followed by JNK-dependent apoptosis 
[3]. Consistent with these findings, the ability of NBDs 
to induce caspase-3 activity was dramatically compro-
mised in the JNK1-silenced clone (Fig. 5a). Furthermore, 
concordant results were obtained when evaluating the 
amount of cells in the sub-G1 phase by flow cytometry. 
Indeed, scramble-transfected cultures had a percentage 
of hypodiploid cells of 2.2 ± 0.1 % which was increased 
Fig. 4 Autophagic flux studies in JNK1-silenced cells. a Western blot for JNK1 in untransfected, scrambled shRNA-transfected and JNK1 shRNA-
transfected cells. β-Actin was used to ensure equal loading and transfer of samples. b Western blot analysis of JNK phospho-activation in cells 
treated with vehicle (CTRL) or 5 μM NBDHEX for the indicated times. The filter was probed with anti-phospho-JNK (p-JNK) and anti-JNK1 antibodies; 
β-actin was used to ensure equal loading and transfer of samples. c Lysates from scrambled shRNA- and JNK1 shRNA-transfected cells treated with 
vehicle (CTRL) or 5 μM NBDHEX for 24 h, incubated or not with 100 nmol/l BAF for 3 h before lysis, were subjected to western blot for LC3-II and 
β-actin. d LC3-II/β-actin ratios as determined from the densitometric analysis of autoradiograms obtained in replicates of the experiment shown in 
c, expressed in arbitrary units (mean ± SEM, n ≥ 3; *p < 0.05 vs. CTRL; #p < 0.05 vs. minus BAF). e Autophagic flux indexes calculated from the data 
illustrated in d as the difference in LC3-II/actin ratios between samples plus and minus BAF (*p < 0.05 vs. CTRL), expressed in arbitrary units (a.u.)
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to 13.7  ±  0.2 and 13.5  ±  0.4  % by the treatment with 
MC3181 and NBDHEX, respectively (Fig.  5b, c). Con-
versely, JNK1-silenced cultures had a proportion of 
hypodiploid cells of about 1 %, which was only margin-
ally increased by the treatment with either compound 
(Fig.  5b, c). Besides, the percentage of cells in G2/M 
arrest following NBDs treatment was much higher in 
JNK1-silenced cultures than in scramble-transfected 
cultures (p  <  0.05) (Fig.  5b, c). Overall, these findings 
indicate that in the absence of JNK signaling the apop-
totic effect of NBDs was abolished.
Discussion
Autophagy is an intracellular catabolic pathway by which 
superfluous or damaged intracellular proteins and orga-
nelles are first engulfed by autophagosomes and then 
delivered to autolysosomes for degradation and recy-
cling of their molecular constituents [39, 40]. Therefore, 
autophagy is deeply involved in cell homeostasis and 
adaptation to stress; by promoting the survival of trans-
formed cells under hypoxic, nutritional and therapeutic 
stress conditions, it plays a major role in the progression 
of established neoplasms [40, 41]. Cancer cells live under 
a strong metabolic pressure due to their high energy 
demand and inefficient energy production; they often 
reside in a microenvironment that provides an inade-
quate supply of oxygen, nutrients and growth factors, so 
that they are predicted to be more susceptible to the sup-
pression of autophagy than non-cancerous cells [29, 39, 
40]. On the other hand, prolonged stress and sustained 
autophagy activation may eventually lead to cell death 
in certain cellular contexts such as in apoptosis-defec-
tive cells [41–43]. Based on such evidence, modulators 
able to induce autophagic cell death or inhibit protec-
tive autophagy are currently being investigated in order 
to manipulate autophagy for clinical benefit in cancer 
patients [41–44]. In this context, autophagy inhibition 
is emerging as a promising therapeutic strategy against 
cancer [41–44]. Moreover, the potential of autophagy 
inhibitors such as CQ to increase tumor cell death upon 
therapeutic stress conditions induced by radiation, geno-
toxic agents, or tumor-targeted agents is documented by 
several studies [41–45].
We here demonstrate that NBD compounds, already 
known to inhibit both the catalytic and TRAF2/JNK1-
sequestering activity of GSTs and to trigger cell cycle 
arrest and apoptosis in cancer cells [4, 5, 14], share the 
ability to act as late-phase autophagy inhibitors. In fact, 
we provide evidence that NBDs induce the accumula-
tion of autophagic vesicles and LC3-II while reducing 
both basal and nutritional stress-induced autophagic 
flux in U-2OS cells. Furthermore, we show that the 
effects of NBDs on autophagy are general rather than 
cell type-specific. Indeed, these compounds produce a 
variable increase of both LC3-II and the autophagy selec-
tive substrate p62 in a panel of tumor cell lines of dif-
ferent origins, the concurrent increase of these markers 
being consistent with an impairment of autophagosome 
clearance [27, 28]. At present we do not know whether 
this effect is due to the inhibition of autophagosome-
lysosome fusion or to the defective degradation of the 
autophagic material in the autophagolysosome [27].
Fig. 5 Cell death studies in JNK1-silenced cells. a Caspase-3 activity 
assay in scrambled shRNA- and JNK1 shRNA-transfected cells treated 
with vehicle (CTRL), 5 μM MC3181 or 5 μM NBDHEX for 24–48 h 
(mean ± SEM, n ≥ 3; *p < 0.05 vs. CTRL). b, c Analysis of DNA content 
by flow cytometry on scrambled shRNA- and JNK1 shRNA-transfected 
cells treated with vehicle (CTRL), 5 μM MC3181 or 5 μM NBDHEX for 
48 h. b A representative experiment with the percentage of sub-G1 
apoptotic cells is shown. c Histograms illustrating the percentage 
of cells in each phase of cell cycle, resulting from four independent 
experiments
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The tumor cell lines used in this study display dif-
ferent degrees of sensitivity to the cytostatic/cytotoxic 
effects of NBDHEX and MC3181, their IC50s for the 
two compounds ranging from about 1 μM for U-2OS to 
about 11–16 μM for HT-29 cells. No evident correlation 
emerges from the comparison of the cell lines’ sensitivity 
to the cytostatic/cytotoxic effects of NBDs and the degree 
of autophagy inhibition induced by the compounds. For 
instance, based on autophagic markers accumulation lev-
els, NBDs induce comparably high levels of autophagy 
impairment in U-2OS and HT-29 cells, which however 
display the lowest and highest IC50 values among the 
cell lines included in the study. Conversely, the IC50s of 
U-2OS, MM-B1 and MCF-7 cells are quite similar, while 
the extent of autophagy inhibition observed in the latter 
two cell lines appears much lower as compared to that 
of U-2OS. On the other hand, this apparent lack of cor-
relation is not conclusive since different cell lines can be 
characterized by different degrees of autophagy addic-
tion and, accordingly, can display marked differences in 
how they respond to autophagy inhibition [29, 44, 46, 
47]. Therefore, experiments performed in a given cell line 
after silencing of essential autophagy genes [27] will be 
necessary to investigate whether and to what extent the 
effects of NBDs on tumor growth and survival actually 
depend on the impairment of the autophagic pathway. In 
any case, our results suggest that the therapeutic poten-
tial of NBDs may not rely solely on their effectiveness in 
inducing cell cycle arrest and apoptosis, but also on their 
ability to weaken the capacity of tumor cells to endure 
stress conditions via autophagy. These findings may bear 
relevance for future studies specifically aimed at evaluat-
ing the efficacy of NBDs on autophagy-dependent tumor 
types as well as for the rational design of combined 
approaches based on the association of NBDs with anti-
tumor drugs known to induce pro-survival autophagy 
[43–45].
A second interesting finding of this study regards the 
role played by JNK in the autophagy-inhibitory effect of 
NBDs. In fact, treatment with NBDs triggers the activa-
tion of JNK, along with other signaling pathways [3, 5, 
14, 21], and leads to autophagic flux impairment. Moreo-
ver, by silencing JNK1 expression in U-2OS cells we here 
provide evidence that autophagy impairment by NBDs 
requires JNK activity: as compared to the untreated cells, 
in JNK1-silenced cells treated with NBDHEX we found an 
increase of LC3-II compatible with an increased formation 
of autophagosomes, but autophagic flux inhibition was no 
longer observed. These results implying a role for JNK in 
mediating autophagy impairment are unexpected given 
that the literature extensively supports the pro-autophagic 
function of this MAPK [35, 36]. In particular, JNK has been 
reported to promote autophagy in response to different 
types of stress signals by two main mechanisms. First, by 
phosphorylating Bcl-2, JNK induces its dissociation from 
the autophagy-regulatory protein Beclin-1 which, in turn, 
interacts with multiple partners to promote the forma-
tion and maturation of autophagosomes [36]. Second, JNK 
activation drives the upregulation of damage-regulated 
autophagy modulator (DRAM), a lysosomal protein whose 
stimulatory role in autophagy is thought to rely on the abil-
ity to regulate the fusion of autophagosomes and lysosomes 
[48]. By contrast, two recent papers report that suppres-
sion of JNK signaling induces autophagy in neurons [37], 
lens fiber cells and MCF-7 cells [38] by decreasing FoxO-
dependent expression of Bnip3, which in turn promotes 
autophagy via the dissociation of Beclin1 from Bcl-xl [37], 
and by acting as a positive regulator of the autophagy 
inhibitor MTORC1 [38]. Therefore, it appears that the 
autophagy inhibitory action of JNK can be mediated by dif-
ferent mechanisms. Besides, a factor that may explain the 
involvement of JNK in the inhibition of autophagy caused 
by NBDs is the JNK-dependent activation of caspases, 
since it has been reported that these proteases can inhibit 
autophagy through the cleavage of essential autophagy 
proteins including Beclin-1 and different Atg proteins 
[49]. The finding that NBDs caused autophagy impairment 
and caspase-3 activation in JNK-positive U-2OS, but no 
autophagic flux inhibition or caspase-3 activation in JNK-
silenced cells supports this hypothesis.
What emerges from this complex scenario is that JNK 
can act at multiple levels in the dynamic multistep pro-
cess of autophagy to generate context-specific responses, 
probably depending on the mode and kinetics of its acti-
vation as well as on the cooperation with different signal 
transduction pathways [37]. In this respect, due to their 
ability to induce the dissociation of both the TRAF2-
GSTP1-1 and JNK-GSTP1-1  complexes, NBDs act as 
multi-target compounds able to activate not only JNK 
but also the TRAF2 downstream target p38 [3, 14, 21], 
which has been reported to act, through mechanisms still 
poorly defined, both as a positive and negative regulator 
of autophagy [35, 36]. Accordingly, the concurrent activa-
tion of different signaling pathways by NBDs may partici-
pate in modulating JNK-dependent responses leading to 
autophagic flux impairment.
Conclusions
This study provides further evidence for the concept 
that, in addition to its well-established role as a positive 
autophagy regulator, JNK can participate in impairing 
autophagy in certain conditions. Furthermore, our dem-
onstration that NBDs can act as late-phase autophagy 
inhibitors unravels an additional favorable property of 
these compounds and opens up new opportunities to 
fully exploit their potential as anticancer agents.
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